PX1 Research provides reference-grade CJC-1295 for qualified academic, institutional, and private laboratory investigators. Manufactured in the United States within ISO 17025 accredited facilities, every batch is verified for identity, purity, and low endotoxin content to ensure analytical reproducibility in preclinical research models.
PX1 Research provides reference-grade CJC-1295 for qualified academic, institutional, and private laboratory investigators. Manufactured in the United States within ISO 17025 accredited facilities, every batch is verified for identity, purity, and low endotoxin content to ensure analytical reproducibility in preclinical research models.
When planning to buy CJC-1295 for laboratory research, investigators require absolute analytical certainty regarding sequence integrity, chemical purity, and endotoxin thresholds. CJC-1295 is a synthetic 29-amino-acid peptide analog of growth-hormone-releasing hormone (GHRH) engineered to demonstrate extended plasma half-life and sustained bioactivity in preclinical models. To maintain reproducibility across cellular assays and animal studies, researchers must source material that has undergone rigorous analytical validation.
PX1 Research synthesizes CJC-1295 (No DAC) and CJC-1295 with DAC in United States manufacturing centers operating under strict quality control standards. Every production lot undergoes independent, third-party testing via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS) to guarantee chemical purity exceeding 98%. Qualified research accounts can access comprehensive analytical documentation directly through our research library hub, ensuring full transparency prior to experimental deployment.
CJC-1295 (also recognized in literature as modified GRF 1-29) is a modified variant of human growth-hormone-releasing factor. The native GHRH (1-29) peptide sequence is inherently susceptible to rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) in physiological environments. To counteract this rapid degradation in preclinical research settings, four specific amino acid substitutions are introduced at positions 2, 8, 15, and 27: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27.
These structural modifications significantly enhance resistance to enzymatic proteolysis while preserving high binding affinity for the GHRH receptor. In scientific literature, CJC-1295 is evaluated in two distinct biochemical configurations:
1. CJC-1295 Without DAC (Modified GRF 1-29): A 29-amino-acid peptide that exhibits an extended half-life compared to native GHRH (approx 30 minutes in rodent models vs. minutes for native GHRH), preserving a semi-pulsatile pattern of GH secretion.
2. CJC-1295 With DAC (Drug Affinity Complex): Incorporates a reactive maleimido derivative attached to a lysine linker at the C-terminus. In vivo or in serum-enriched assays, the maleimide group covalently binds to circulating serum albumin, extending the half-life to several days in animal studies.
Understanding these structural distinctions is crucial when researchers choose to buy CJC-1295, as the presence or absence of the Drug Affinity Complex fundamentally alters the pharmacokinetic profile and downstream receptor signaling kinetics in vitro and in vivo.
In vitro data indicate that CJC-1295 acts as a selective agonist at the growth-hormone-releasing hormone receptor (GHRHR), a class B G-protein-coupled receptor located primarily on the plasma membrane of anterior pituitary somatotrophs. Upon ligand binding, the receptor undergoes a conformational change that stimulates the Gs alpha subunit, activating intracellular adenylyl cyclase.
This enzymatic activation converts adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP), triggering downstream activation of protein kinase A (PKA). The PKA signaling cascade promotes intracellular calcium influx through voltage-gated channels and stimulates the transcription factor CREB (cAMP response element-binding protein). Preclinical studies suggest that this cascade upregulates the transcription and exocytosis of stored growth hormone (GH) vesicles.
Unlike direct GH secretagogues that bypass physiological feedback loops, GHRH analogs rely on native pituitary machinery. When evaluating cellular response curves in GHRH analogs research, investigators observe that CJC-1295 sustained receptor occupancy stimulates continuous transcription of downstream signals, including insulin-like growth factor 1 (IGF-1) in hepatocyte cultures and rodent tissue models.
In academic literature, CJC-1295 is extensively studied as a long-acting growth-hormone-releasing hormone analog designed to sustain GH and downstream IGF-1 levels for tissue repair research. Animal models evaluating metabolic homeostasis, nitrogen balance, and cellular regeneration frequently utilize CJC-1295 to investigate the broad physiological implications of elevated axis activity.
Rodent studies have demonstrated that chronic administration of CJC-1295 leads to dose-dependent increases in total pituitary GH mRNA expression and circulating IGF-1 concentrations without inducing somatotroph hyperplasia. These elevations are correlated in literature with enhanced chondrocyte proliferation, accelerated collagen synthesis, and improved nitrogen retention in injured musculoskeletal tissue models.
Furthermore, preclinical models examining body composition have recorded reductions in visceral adipose tissue mass accompanied by increases in lean tissue accrual following sustained exposure to long-acting GHRH agonists. Researchers analyzing cellular repair mechanisms frequently examine tissue repair compounds alongside CJC-1295 to measure synergistic impacts on fibroblast migration and extracellular matrix deposition.
When structuring experimental protocols around the growth hormone axis, researchers often evaluate CJC-1295 alongside alternative peptides within the growth hormone secretagogue and GHRH agonist classes. Selecting the appropriate research tool depends on whether a pulsatile or sustained signal is required for the specific assay.
A primary point of comparison involves ipamorelin, a selective ghrelin receptor (GHS-R1a) agonist. While CJC-1295 acts on the GHRH receptor, ipamorelin activates a distinct pathway that stimulates GH secretion without elevating cortisol or prolactin levels in animal models. Frequently, literature examines the co-administration of CJC-1295 and ipamorelin to observe dual-receptor synergy in vitro.
Additionally, investigators compare CJC-1295 with sermorelin, the unmodified native GHRH (1-29) fragment. Sermorelin displays a rapid clearance rate in plasma (half-life < 12 minutes in rodent models), making it suitable for studies requiring acute, transient secretagogue pulses. Conversely, tesamorelin—a hexenoyl-modified GHRH analog—is optimized for hepatic lipolysis assays and metabolic syndrome models due to its specific lipolytic potency. Researchers evaluating these options can explore our complete catalog of research peptides to select compounds matched to their precise protocol requirements.
The utility of preclinical research depends directly on the analytical purity and consistency of the chemical reagents employed. Inferior synthesis, residual trifluoroacetic acid (TFA), organic solvents, or bacterial endotoxin contamination can confound experimental assays, induce cytotoxicity, or yield false-positive inflammatory responses in cell cultures.
At PX1 Research, every production run of CJC-1295 undergoes rigorous analytical validation prior to release:
- High-Performance Liquid Chromatography (RP-HPLC): Establishes chemical purity profiles. We require a minimum purity threshold of ≥98.0%, ensuring the absence of truncated sequences or deletion peptides.
- Mass Spectrometry (ESI-MS): Confirms exact molecular weight (3367.97 Da for modified GRF 1-29 sequence) to verify identity.
- Endotoxin Testing (LAL Assay): Crucial for cell culture and in vivo research, our peptides are verified to contain <0.01 EU/mg, preventing lipopolysaccharide-induced inflammatory signaling.
- Lot-Specific Certificate of Analysis (COA): Every vial shipped from our USA facilities (located in California and Arizona) includes direct access to verifiable lot documentation.
By maintaining manufacture within ISO 17025 accredited, GMP-compliant facilities, PX1 Research provides qualified institutional laboratories with reference-grade material that satisfies stringent methodological standards.
CJC-1295 is supplied as a lyophilized (freeze-dried) powder under inert gas flushing to maximize shelf stability. To maintain structural integrity and prevent peptide degradation during laboratory preparation, researchers should adhere to standardized handling protocols.
Lyophilized vials should be stored at -20°C or -80°C for long-term stability, protected from light exposure. Prior to reconstitution, vials should be allowed to equilibrate to room temperature inside a laminar flow hood to minimize condensation formation inside the container.
Reconstitution should be performed using sterile laboratory-grade solvents, such as 0.9% bacteriostatic water (containing 0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS), depending on the requirements of the downstream assay. The solvent should be directed down the glass wall of the vial rather than sprayed directly onto the lyophilized cake. Gentle swirly or slow inversion is recommended; vigorous agitation or vortexing must be avoided to prevent mechanical shearing of the peptide chain.
Once reconstituted, aqueous solution aliquots should be stored at 2°C to 8°C for short-term evaluation or flash-frozen in single-use working volumes at -80°C to prevent degradation through repeated freeze-thaw cycles. Detailed reconstitution matrices and molarity calculators are available in our growth hormone secretagogues research guide.
For universities, biotechnology firms, and contract research organizations (CROs) requiring large-scale reagent supply, PX1 Research offers streamlined procurement solutions. Maintaining single-source consistency across long-term animal trials or multi-phase cellular studies is essential to eliminate batch-to-batch variance.
All orders ship directly from our centralized logistics centers in California and Arizona. Orders placed before cut-off times Monday through Friday are processed for same-day dispatch via expedited courier services to ensure rapid delivery under temperature-controlled conditions.
Institutions seeking high-volume orders or recurring batch reservations can establish dedicated supply lines through our wholesale laboratory portal. Account representatives provide custom lot reservation, protocol-matched CoA archiving, and direct technical support for qualified scientific personnel.
What is the purity level of CJC-1295 from PX1 Research?
PX1 Research guarantees a chemical purity of ≥98.0% for all CJC-1295 lots, as verified by independent RP-HPLC analysis and ESI-MS mass spectrometry.
What is the difference between CJC-1295 with DAC and CJC-1295 without DAC?
CJC-1295 without DAC (modified GRF 1-29) has a shorter half-life (~30 minutes in rodent models), promoting a semi-pulsatile GH release pattern. CJC-1295 with DAC includes a maleimide complex that covalently binds serum albumin, extending the half-life to several days in animal models.
What endotoxin controls are applied to PX1 Research CJC-1295?
Every lot undergoes Chromogenic LAL testing to verify endotoxin levels are below <0.01 EU/mg, making it suitable for sensitive cell culture assays and preclinical models.
How should lyophilized CJC-1295 be stored upon arrival?
Lyophilized CJC-1295 should be stored at -20°C or -80°C in a dry environment protected from light. Under these conditions, the un-reconstituted peptide remains stable for up to 24 months.
What solvent is recommended for reconstituting CJC-1295 for laboratory work?
Reconstitution is typically performed using sterile bacteriostatic water (0.9% benzyl alcohol) for extended reconstituted stability, or sterile PBS for immediate cell culture applications.
Where does PX1 Research manufacture and ship CJC-1295?
All CJC-1295 peptides are synthesized in US-based, ISO 17025 accredited facilities and shipped directly from our warehouse hubs in California and Arizona.
Can I obtain a lot-specific Certificate of Analysis for my order?
Yes. Every shipment includes lot-matched tracking details, and digital Certificates of Analysis containing full HPLC chromatograms and mass spectra are available through our online database.
Is CJC-1295 approved for human consumption or therapeutic use?
No. CJC-1295 provided by PX1 Research is strictly sold as a research chemical for qualified laboratory, in vitro, and preclinical research use only. It is not for human or veterinary use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.